12/19
07:42 am
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $14.00.
Medium
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $14.00.
12/13
07:07 am
glue
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors [Yahoo! Finance]
12/13
07:00 am
glue
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Medium
Report
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
12/11
07:10 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer [Yahoo! Finance]
12/11
07:10 am
glue
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders [Yahoo! Finance]
12/11
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
12/11
07:00 am
glue
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
High
Report
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
12/5
07:07 am
glue
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors [Yahoo! Finance]
12/5
07:00 am
glue
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Low
Report
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
11/26
07:00 am
glue
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Low
Report
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
11/21
04:26 am
glue
NLRP3 Protein Inhibitors Pipeline Research Report 2024: Therapeutic Assessment of 25+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Medium
Report
NLRP3 Protein Inhibitors Pipeline Research Report 2024: Therapeutic Assessment of 25+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/13
12:41 pm
glue
NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]
Medium
Report
NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]
11/13
07:00 am
glue
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Medium
Report
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
11/11
08:08 am
glue
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), [Yahoo! Finance]
Low
Report
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), [Yahoo! Finance]
11/7
10:32 am
glue
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/7
07:00 am
glue
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/6
01:26 pm
glue
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice [Yahoo! Finance]
Low
Report
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice [Yahoo! Finance]
10/28
03:04 pm
glue
This Biotech Stock Has Doubled Its Value Today—Here's Why [Yahoo! Finance]
High
Report
This Biotech Stock Has Doubled Its Value Today—Here's Why [Yahoo! Finance]
10/28
08:48 am
glue
Why Is Monte Rosa Therapeutics Stock Surging On Monday? [Yahoo! Finance]
High
Report
Why Is Monte Rosa Therapeutics Stock Surging On Monday? [Yahoo! Finance]
10/28
07:00 am
glue
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
High
Report
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
10/23
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
Medium
Report
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors